Table 1

Demographic data at baseline

Variable

C-SLE trained

(n = 10)

C-SLE non-trained

(n = 9)

Control

(n = 10)


Age, years

12.9 (2.3)

13.0 (1.8)

12.0 (1.8)

Body weight, Kg

48.7 (10.1)

49.7 (12.1)

46.6 (14.5)

Height, m

1.48 (0.09)

1.44 (0.11)

1.51 (0.13)

Body mass index, Kg/m2

22.3 (3.8)

23.9 (3.4)

21.2 (1.7)

Pubertal stages I/II/III/IV/V, number of individuals

1/2/2/2/3

0/2/3/2/2

3/2/1/2/2

SLEDAI-2K, score

5.3 (5.3)

5.6 (6.4)

NA

SLICC/ACR-DI, score

0.4 (0.7)

0.4 (0.7)

NA

Disease duration, years

3.3 (2.6)

4.3 (2.6)

NA

Current dose of prednisone, mg/d

19.8 (17.0)

15.5 (7.7)

NA

Cumulative dose of prednisone, g

13.7 (6.7)

20.9 (13.0)

NA

Current dose of azathioprine, mg/d

128.6 (39.3)

121.4 (17.2)

NA

Cumulative dose of azathioprine, g

58.2 (32.1)

62.2 (41.1)

NA

Current dose of chloroquine, g/d

205.8 (51.2)

205.6 (51.2)

NA

Cumulative dose of chloroquine, g

129.7 (119.9)

181.3 (121.5)

NA

Drugs, number of patients (%)

Prednisone

10 (100)

9 (100)

Fluoxetine

1 (10)

0 (0)

NA

Diltiazen

1 (10)

0 (0)

NA

Enalapril

3 (30)

5 (55)

NA

Losartan

1 (10)

1 (11)

NA

Anlodipine

0 (0)

2 (22)

NA

Carbamazepine

1 (10)

0 (0)

NA

Methylphenidate

0 (0)

0 (0)

NA

Clopidogrel

0 (0)

0(0)

NA

Warfarin

1(10)

0(0)

NA

Acetylsalicylic Acid

1 (10)

0 (0)

NA


Results are presented as mean (SD) unless stated otherwise. C-SLE, childhood-onset systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/ACR Damage Index; NA, not applicable.

Prado et al. Arthritis Research & Therapy 2013 15:R46   doi:10.1186/ar4205

Open Data